Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

Inclusion Criteria: Both HIV infected and HIV uninfected individuals are eligible for this study. * CD4 cell count of 400 cells/mm3 or greater at study entry * If HIV infected, initiated anti-HIV medicines within 120 days of infection * If HIV infected, HIV viral load \< 50 copies/ml for at least 3 months prior to study entry * Current medication regimen for at least 3 months prior to study entry * A particular blood type (HLA-A\*0201) * Acceptable methods of contraception Exclusion Criteria: * Received investigational drug or vaccine within 30 days prior to study entry * On other immune-based therapy (e.g., interleukin-2, alpha interferon, immunoglobulin, thalidomide) within 30 days prior to study entry * Megesterol acetate within 30 days prior to study entry * Immunization within 4 weeks of study entry * If hepatitis B virus (HBV) uninfected and at high risk for HBV infection, the patient will not be eligible until he or she has completed an HBV vaccine series. * Unstable or severe medical condition, including active opportunistic infection requiring treatment * History of Hashimoto's thyroiditis * Cancer requiring chemotherapy within 6 months prior to study entry * History of radiation therapy to axillary lymph nodes * Significant laboratory abnormalities at study entry * Pregnant or breastfeeding * History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, autoimmune hepatitis, scleroderma, mixed connective tissue disorder) * Allergy to gentamicin, tobramycin, streptomycin, or amikacin